NasdaqGS:BMRNBiotechs
What BioMarin Pharmaceutical (BMRN)'s Voxzogo Trial Stops and Mixed Safety Data Mean For Shareholders
Recently, BioMarin Pharmaceutical discontinued three Phase 2 Voxzogo studies following safety concerns, while simultaneously reporting encouraging clinical and real-world outcomes for the drug in other settings.
The company and analysts now suggest that Voxzogo’s safety issues may be limited to specific uses, with BioMarin’s broader outlook increasingly supported by its wider rare-disease portfolio.
Now we’ll explore how the Voxzogo safety-driven trial discontinuations, alongside positive...